Tender Details

Country: Germany
Summary: Completion of a Non-exclusive Discount Agreement According to § 130a (8) Sgb V for the Active Substance Dasatinib (excluding Patent-free Indication), Atc L01xe06), for the Period 1.4.2021-31.3.2023
DET Ref No: 50424404
Deadline: 05 Feb 2023
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: 1.00
Notice Type: Tender
Document Ref. No.: 084920-2021
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
Document Type: Contract Notice
Title: Completion of a non-exclusive discount agreement according to § 130a (8) SGB V for active substance Dasatinib (exclusively patent-free indication), ATC L01XE06), for the time 1.4.2021-31.3.2023
Reference Number: 1003210 - Dasatinib (exclusively patent-free indication), ATC L01XE06
Contract Type: Supplies
Estimated Value: 1.00 - EUR
Description: § 130a paragraph 8 SGB V enables the health insurance companies and pharmaceutical companies to enclose framework accounts for the medicinal products to be deducted from the statutory health insurance companies. With regard to the relevant statutory provisions on the award of public procurement, a regular process of drug-related, formal procurement procedures takes place according to the regulations of the 4th part of the GWB by DAK health. For from the tenderer closer to Appendix 2 to the Treaty to the Treaty to the o. G. Active substance (Dasatinib (exclusively patent-free indication), ATC L01XE06) intends to share the DAK health until the entry into force of new drug discount agreements with as all interested pharmaceutical companies as possible of pharmaceutical companies ...
Documents:

If you are registered member, kindly login to view full details of this tender notice:

Completion of a Non-exclusive Discount Agreement According to § 130a (8) Sgb V for the Active Substance Dasatinib (excluding Patent-free Indication), Atc L01xe06), for the Period 1.4.2021-31.3.2023 - Germany Tender

The DAK HEALTH, a Government sector organization in Germany, has announced a new tender for Completion of a Non-exclusive Discount Agreement According to § 130a (8) Sgb V for the Active Substance Dasatinib (excluding Patent-free Indication), Atc L01xe06), for the Period 1.4.2021-31.3.2023. This tender is published on GermanyTenders under DET Ref No: 50424404 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2023-02-05.

The estimated tender value is 1.00, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.